Boston Scientific: Old Age is a Growth Stock

by

Let’s be honest, aging isn’t exactly a glamorous topic. But it is predictable. Like taxes, or that awkward moment when you realize your parents are, in fact, not the infallible beings you once believed. And predictability, my friends, is a beautiful thing for an investor. Especially when the World Health Organization is practically handing you a demographic trend on a silver platter. They’re saying the over-60s are going to nearly double by 2050. Double. That’s a lot of creaky joints and failing organs. And a rather handsome opportunity, if you ask me.

Boston Scientific (BSX 1.07%) isn’t exactly a name that sets pulses racing, is it? It’s not the shiny new tech everyone’s clamoring for. Which, frankly, is exactly why I like it. It’s quietly, reliably, addressing the realities of… well, becoming obsolete. And that’s a business model I can get behind. Or, at least, invest in.

1. They’ve Been Preparing for This, Honestly

Boston Scientific didn’t just wake up and decide to cater to the elderly. They’ve been quietly cornering the market on things that fall apart as we do. Take the Watchman line. Tiny little heart inserts to prevent strokes in people with atrial fibrillation. It’s not exactly thrilling, but it’s a growing problem for those of us heading towards… let’s say, ‘senior status.’ And they launched it in 2015. They saw this coming.

Then there’s neuromodulation. Basically, zapping people’s nerves to alleviate pain. Chronic pain, the kind that comes with degenerative disorders. It’s not pretty, but it’s a massive market. And they’re good at it. They even have a system – Vercise Deep Brain Stimulation – to help with Parkinson’s tremors. Honestly, the fact that anyone can still manage to hold a teacup at 80 is a medical miracle. They’re just making it a slightly more reliable miracle.

2. Expanding the Portfolio – Because Even Old Businesses Need a Side Hustle

They aren’t resting on their laurels, either. Boston Scientific is branching out, picking up bits and pieces that complement their existing business. The recent acquisition of Penumbra for a cool $14.5 billion? That’s about removing blood clots – thrombectomy, to be precise. Strokes are a big problem for the aging population, and Penumbra has the tech to fix them. It’s a logical move. Like adding a stairlift to a house already full of orthopedic cushions.

And then there’s Silk Road Medical, acquired in September 2024. They’ve invented a procedure to clear blocked arteries. It’s called transcarotid artery revascularization (TCAR). Fancy name, but it basically means keeping people alive a little longer. They’re covering all the bases, really. Prevention and cure. It’s almost… unsettlingly efficient.

3. The Market Overreacted. Seriously.

Here’s where it gets interesting. Boston Scientific reported solid earnings last quarter. Double-digit revenue and profit growth. Beat expectations. Everything you’d want to see. But then, management dared to predict annual growth of only 10.5% to 11.5% for 2026. The horror! The stock plummeted 17%. Honestly, the market can be so dramatic. It’s like a toddler throwing a tantrum because you won’t give them another cookie.

Loading widget...

This overreaction has left the stock ridiculously undervalued. The forward P/E is just over 22, giving it a five-year PEG ratio of 0.85. Anything below 1 suggests it’s a bargain. And given their consistent growth and prime positioning in this demographic goldmine, it is a bargain. It’s the kind of discount that makes me feel slightly guilty… and then I remind myself that the market is irrational, and I’m just being sensible.

So, yes, Boston Scientific isn’t glamorous. It’s not going to make you rich overnight. But it’s a solid, dependable company addressing a predictable trend. And in a world obsessed with hype and innovation, sometimes the most profitable thing you can do is invest in… old age. It’s a bit morbid, perhaps. But also, brilliantly logical.

Read More

2026-03-05 21:23